NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective lowered by Citigroup from $13.00 to $8.00 in a ...

Applied Therapeutics (NASDAQ:APLT – Free Report) had its price objective reduced by Robert W. Baird from $14.00 to $5.00 in a ...

The news, announced just after market close Nov. 27, ahead of the Thanksgiving holiday in the U.S., sent shares (NASDAQ:APLT) falling 76% Friday, Nov. 29. The stock opened Dec. 2 down another 10%.

Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...

U.S. equities headed to Friday's early close—and the conclusion of November trading—in positive territory as the ...

Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...